Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 10.64
- Piotroski Score 5.00
- Grade Overweight
- Symbol (LLY)
- Company Eli Lilly and Company
- Price $923.40
- Changes Percentage (-1.24%)
- Change -$11.62
- Day Low $922.10
- Day High $942.35
- Year High $972.53
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Last Earnings 06/24/2024
- Ex-Dividend for 5/16 Dividend 08/15/2024
- Dividend Payable 09/10/2024
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $870.50
- High Stock Price Target $1,150.00
- Low Stock Price Target $300.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $6.78
- Trailing P/E Ratio 125.37
- Forward P/E Ratio 125.37
- P/E Growth 125.37
- Net Income $5.24 B
Income Statement
Quarterly
Annual
Latest News of LLY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Maryland Weather: Beautifully bright and warm for Ravens game
Sunny skies and mild temperatures in the low 80s for the Ravens home-opener. Clouds may mix in but overall a perfect forecast. Cooler temps at night. Clouds increase on Monday with a chance of a stray...
By CBS News | 10 hours ago -
You need to start paying your student debt. No, really.
Student loan borrowers face credit score consequences if they don't start repaying soon. President Biden's 12-month repayment "on-ramp" ends on Sept. 30. About 10 million Americans risk credit score h...
By USA Today | 11 hours ago -
African Rainbow Minerals' (JSE:ARI) Soft Earnings Are Actually Better Than They Appear
African Rainbow Minerals' recent weak earnings report didn't impact its stock significantly. Unusual items affecting profit and a tax benefit might distort earnings. Investors should consider underlyi...
By Yahoo! Finance | 12 hours ago
